The Latest Cardiac and Vascular News
PAIRS, Oct. 28, 2024 /PRNewswire/ — On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the…
NANJING, China, Oct. 25, 2024 /PRNewswire/ — On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with…
NEW YORK, Oct. 22, 2024 /PRNewswire/ — Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of “large…
A First in the Middle East and North Africa
KFSHRC Launches Mobile Stroke Unit to Accelerate Patient Treatment
SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced acceptance of an oral presentation on the potential of troculeucel in patients with neurodegenerative disease and stroke, at the 16th World Stroke Congress (“WSC 2024”) to be held in Abu Dhabi, UAE from October 23–26, 2024. Although accepted as an oral presentation, NKGen has opted to showcase troculeucel results in poster format.
ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company’s…
SAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today filed a patent infringement lawsuit against Q’Apel Medical alleging infringement of five U.S. patents held by Route 92 Medical, which protect the Tenzing® delivery catheter. The complaint was filed October 7, 2024, in the United States District Court for the District of Delaware.
NEW YORK, Oct. 1, 2024 /PRNewswire/ — Remedy Pharmaceuticals today announced additional promising data from the Phase 3 CHARM clinical trial of CIRARA (IV glyburide) in patients with Large Hemispheric Infarction (LHI), the most serious form of ischemic stroke, characterized by…
NEW YORK–(BUSINESS WIRE)–Synchron, a brain-computer interface company, today announced positive results from the COMMAND study evaluating the safety and efficacy of the Synchron brain computer interface (BCI) device in six participants over a 12-month period. “The COMMAND study results represent a major medical milestone, confirming the safety of the Stentrode […]
Gene therapy delivered via CereVasc’s endovascular delivery approach reached key targets in the central nervous system after injection into the cerebellopontine angle resulting in broad biodistribution The eShunt approach has the potential to provide doctors and biopharma partners with a…
